Nunn Jason Raleigh 4
4 · Zenas BioPharma, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Zenas BioPharma Director Jason Nunn Receives Award (18,500 shares)
What Happened
Jason Raleigh Nunn, a director of Zenas BioPharma, was granted 18,500 derivative share awards on June 15, 2026. The Form 4 (filed June 17, 2026) reports an acquisition at $0.00 per share (transaction code A — award/grant). No cash was paid in this reported grant; the award’s economic value will depend on future share price and vesting.
Key Details
- Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely filing).
- Transaction type/code: Grant/Award (A) of derivative securities.
- Amount: 18,500 underlying shares reported as acquired at $0.00 (reported value $0).
- Vesting: Footnote F1 — vests 100% on June 15, 2027 (first anniversary of vesting commencement), subject to continued service.
- Shares owned after transaction: not specified in the provided filing.
- Not an open-market purchase or sale; this is a compensation equity grant, not an immediate cash transaction.
Context
This filing documents a compensation award (derivative equity such as stock options or RSUs) rather than a market purchase or sale. Such grants are standard for directors and reflect compensation terms (subject to service-based vesting); they do not by themselves indicate the insider buying or selling shares on the open market.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-15+18,500→ 18,500 totalExercise: $18.71Exp: 2036-06-15→ Common Stock (18,500 underlying)
Footnotes (1)
- [F1]The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.